Examination of Efficacy and Safety of Baricitinib in RA Patients
NCT ID: NCT03755466
Last Updated: 2021-09-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
90 participants
INTERVENTIONAL
2018-11-21
2025-11-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Baricitinib treatment for 12 months
2. Biologics treatment for 12 months
3. Tofacitinib treatment for 12 months
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study in Moderate to Severe Rheumatoid Arthritis
NCT01710358
Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy
NCT01469013
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
NCT01711359
BARIcitinib Cognitive Emotional and Neural signaTuRE
NCT05238896
A Moderate to Severe Rheumatoid Arthritis Study
NCT01721044
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BARI
"Biologics"
To examine the effects of biologics in RA patients
Tofacitinib 5 MG [Xeljanz]
To examine the effects of tofacitinib in RA patients
Bio
"Baricitinib", "olumiant®"
To examine the effects of baricitinib in RA patients
Tofacitinib 5 MG [Xeljanz]
To examine the effects of tofacitinib in RA patients
Tofa
"Baricitinib", "olumiant®"
To examine the effects of baricitinib in RA patients
"Biologics"
To examine the effects of biologics in RA patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
"Baricitinib", "olumiant®"
To examine the effects of baricitinib in RA patients
"Biologics"
To examine the effects of biologics in RA patients
Tofacitinib 5 MG [Xeljanz]
To examine the effects of tofacitinib in RA patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* RA patients who are allergic to the drugs, refused to do this research, or who are pregnant
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shinshu University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yukio Nakamura
Lecturer at Shinshu University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yukio Nakamura
Matsumoto, Nagano, Japan
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BARI2018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.